Suit Says Makers of Testosterone Drug AndroGel Hid Risks of Blood Clots, Stroke

PHILADELPHIA — A new suit filed in Pennsylvania federal court accuses the makers of AndroGel of hiding serious health risks associated with the testosterone replacement drug, including deep vein thrombosis, stroke and death.

The Feb. 12 complaint, filed in the U.S. District Court for the Eastern District of Pennsylvania against Abbott Laboratories Inc. and its subsidiary, AbbVie Inc., says AndroGel use may increase the incidence of myocardial infarctions and death by more than 500 percent.

According to the suit, Miami resident Rafael Tejeda Jr. was prescribed AndroGel when he was 45 to treat symptoms associated with low testosterone. He says …